Cargando…

Efficacy of apatinib 250 mg combined with chemotherapy in patients with pretreated advanced breast cancer in a real-world setting

OBJECTIVES: This study evaluated the efficacy and safety of apatinib (an oral small-molecule tyrosine kinase inhibitor targeting VEGFR-2) 250 mg combined with chemotherapy in patients with pretreated metastatic breast cancer in a real-world setting. PATIENTS AND METHODS: A database of patients with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Ruyan, Chen, Yifei, Liu, Xiaoran, Gui, Xinyu, Zhu, Anjie, Jiang, Hanfang, Shao, Bin, Liang, Xu, Yan, Ying, Zhang, Jiayang, Song, Guohong, Li, Huiping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10314217/ https://www.ncbi.nlm.nih.gov/pubmed/37397355 http://dx.doi.org/10.3389/fonc.2023.1076469

Ejemplares similares

Prognostic Value of Pretreatment Neutrophil-to-Lymphocyte Ratio in HER2-Positive Metastatic Breast Cancer
por: Shao, Bin, et al.
Publicado: (2022)

Pegylated liposomal doxorubicin (Duomeisu(®)) monotherapy in patients with HER2-negative metastatic breast cancer heavily pretreated with anthracycline and taxanes: a single-arm, phase II study
por: Jiang, Hanfang, et al.
Publicado: (2023)

Efficacy and Safety of Fulvestrant 500mg in Hormone-receptor Positive Human Epidermal Receptor 2 Negative Advanced Breast Cancer: A Real-world Study in China
por: Lei, Wen, et al.
Publicado: (2020)

Bilateral breast cancer in China: A 10‐year single‐center retrospective study (2006–2016)
por: Jiang, Hanfang, et al.
Publicado: (2021)

The prognostic value of chemotherapy or endocrine therapy choice according to circulating tumor cell count in HR(+)HER2(−) metastatic breast cancer: a retrospective study
por: Shao, Bin, et al.
Publicado: (2022)

Multicenter phase II study of apatinib single or combination therapy in HER2-negative breast cancer involving chest wall metastasis
por: Li, Huiping, et al.
Publicado: (2021)

The prognostic value of neutrophil-to-lymphocyte ratio in de novo stage IV breast cancer: a retrospective cohort study
por: Shao, Bin, et al.
Publicado: (2023)

Efficacy of lapatinib combined with capecitabine in patients with HER2-positive metastatic breast cancer in a real-world study
por: Gui, Xinyu, et al.
Publicado: (2020)

Long term use of bevacizumab in the treatment of triple negative breast cancer with giant tumor in chest wall: A case report
por: Gui, Xinyu, et al.
Publicado: (2018)

Clinicopathological features and prognosis of patients with pregnancy‐associated breast cancer: A matched case control study
por: Zhang, Ruyan, et al.
Publicado: (2021)

Effectiveness, safety, and impact on quality of life of eribulin‐based therapy in heavily pretreated patients with metastatic breast cancer: A real‐world analysis
por: Gui, Xinyu, et al.
Publicado: (2023)

Apatinib combined with chemotherapy in patients with previously treated advanced breast cancer: An observational study
por: Zhu, Anjie, et al.
Publicado: (2019)

Real-World Data on Apatinib Efficacy - Results of a Retrospective Study in Metastatic Breast Cancer Patients Pretreated With Multiline Treatment
por: Liu, Zhaoyun, et al.
Publicado: (2021)

Identification of recurrent BRCA1 mutation and its clinical relevance in Chinese Triple‐negative breast cancer cohort
por: Liu, Xiaoran, et al.
Publicado: (2017)

The anti-tumor efficiency of low-dose apatinib-based chemotherapy in pretreated HER2-negative breast cancer with brain metastases
por: Chen, Xuelian, et al.
Publicado: (2023)

Activity of preclinical and phase I clinical trial of a novel androgen receptor antagonist GT0918 in metastatic breast cancer
por: Li, Huiping, et al.
Publicado: (2021)

Efficacy and safety of trastuzumab combined with chemotherapy for first-line treatment and beyond progression of HER2-overexpressing advanced breast cancer
por: Li, Huiping, et al.
Publicado: (2016)

A Study Of Efficacy And Safety With Apatinib Or Apatinib Combined With Chemotherapy In Recurrent/advanced Ovarian Cancer Patients
por: Yang, Mi, et al.
Publicado: (2019)

Final Overall Survival: Fulvestrant 500mg vs 250mg in the Randomized CONFIRM Trial
por: Leo, Angelo Di, et al.
Publicado: (2013)

First-line chemotherapy with docetaxel plus capecitabine followed by capecitabine or hormone maintenance therapy for the treatment of metastatic breast cancer patients
por: LIANG, XU, et al.
Publicado: (2015)

Efficacy and safety for Apatinib treatment in advanced gastric cancer: a real world study
por: Zhang, Yong, et al.
Publicado: (2017)

$250 Prize: Competition Open to All the World
Publicado: (1887)

1490. Vancomycin 125 mg vs. 250 mg for the Treatment of Non-Severe and Severe Clostridium difficile Infections
por: Hsu, Amy, et al.
Publicado: (2019)

Phase II study of apatinib in combination with oral vinorelbine in heavily pretreated HER2-negative metastatic breast cancer and clinical implications of monitoring ctDNA
por: Zhu, Anjie, et al.
Publicado: (2021)

Pharmacokinetic properties and bioequivalence of gefitinib 250 mg in healthy Korean male subjects
por: Moon, Seol Ju, et al.
Publicado: (2021)

Efficacy and Tolerability of Erlotinib 100 mg/d vs. Gefitinib 250 mg/d in EGFR-Mutated Advanced Non-small Cell Lung Cancer (E100VG250): An Open-Label, Randomized, Phase 2 Study
por: Zhao, Shen, et al.
Publicado: (2020)

Response to apatinib in chemotherapy-failed advanced spindle cell breast carcinoma
por: Zhou, Na, et al.
Publicado: (2016)

Efficacy and Safety of Apatinib in Advanced Hepatocellular Carcinoma: A Multicenter Real World Retrospective Study
por: Zheng, Zhuangzhuang, et al.
Publicado: (2022)

Effectiveness and safety of low‐dose apatinib in advanced gastric cancer: A real‐world study
por: Du, Yingying, et al.
Publicado: (2020)

The efficacy and safety of apatinib in patients with heavily pretreated end-stage cancer: a retrospective study
por: Li, Zhenyu, et al.
Publicado: (2023)

Fulvestrant 500 mg vs 250 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer: a randomized, double-blind registrational trial in China
por: Zhang, Qingyuan, et al.
Publicado: (2016)

Rational for Drug Dosimetry and Duration of Terbinafine in the Context of Recalcitrant Dermatophytosis: Is 500 mg Better than 250 mg OD or BD?
por: Sardana, Kabir, et al.
Publicado: (2017)

Successful treatment of ovarian cancer with apatinib combined with chemotherapy: A case report
por: Zhang, Mingzi, et al.
Publicado: (2017)

Apatinib plus chemotherapy for non-metastatic osteosarcoma: a retrospective cohort study
por: Wang, Jiaqiang, et al.
Publicado: (2023)

Apatinib plus etoposide in pretreated patients with advanced triple-negative breast cancer: a phase II trial
por: Cao, Mengru, et al.
Publicado: (2023)

Clinical effects of Apatinib combined with DOS neoadjuvant chemotherapy regimen in neoadjuvant chemotherapy for LAGC
por: Zhou, Peng-zhe, et al.
Publicado: (2021)

Should the dose of tenofovir be reduced to 200–250 mg/day, when combined with protease inhibitors?
por: Hill, Andrew, et al.
Publicado: (2014)

Combination of apatinib mesylate and second-line chemotherapy for treating gastroesophageal junction adenocarcinoma
por: Lu, Bin, et al.
Publicado: (2019)

Efficacy And Safety Of Apatinib Treatment In Platinum-Resistant Recurrent Epithelial Ovarian Cancer: A Real World Study
por: Zhang, Jindi, et al.
Publicado: (2019)

Efficacy and safety of apatinib in patients with previously treated metastatic colorectal cancer: a real-world retrospective study
por: Gou, Miaomiao, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_dnepshponlqcafhub09pvu82dg